BioInvent International

BioInvent is a clinical-stage biotech company (Nasdaq Stockholm: BINV) that translates cancer antibody biology into innovative immuno-oncology therapies.

[BioInvent International @BioInvent]

BioInvent announces first patient enrolled in Phase 1b/2a study of BI-1607 in combination with ipilimumab and KEYTRUDA (pembrolizumab) in patients with unresectable or metastatic melanoma https://t.co/VsMLL8HdaR

[BioInvent International @BioInvent]

BioInvent International AB: Interim report January–September 2024 is out. Read the report: https://t.co/YOsHvqCLB3

[Pareto Securities @ParetoSec]

Many overlook the importance of toxicity. Martin Welschof, CEO of BioInvent says: Toxicity is as crucial as efficacy. You can’t use what kills you.' A reminder that safety is at least as important as effectiveness in treatments.

@BioInvent $BINV is one of the presenting companies at our 15th annual Healthcare Conference today. For all our BioInvent research, access our research and online trading platform (for clients): https://t.co/TWmQ7Ox03E

[BiotechTV @BiotechTV]

From Stockholm: @bioinvent's CEO highlights TNFR2 data recently presented at #ESMO24, and more in the company's pipeline.

Full video: https://t.co/NdpPnaE05s

[BioInvent International @BioInvent]

Busy days #ESMO2024 - European Society for Medical Oncology 2024 - in Barcelona. Today, the BioInvent team presents a Trial in Progress poster for the company’s second anti-TNFR2 antibody, BI-1910. Read the full poster: https://t.co/HHcC2ajea5

[BioInvent International @BioInvent]

BioInvent and Transgene’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase 1/2a Trial in Solid Tumors that Failed Previous Treatments
https://t.co/cW9FYSr68C

[BioInvent International @BioInvent]

BioInvent announces the enrollment of the first patient in triple combination arm of BI-1206, rituximab and Calquence® for the treatment of non-Hodgkin's lymphoma https://t.co/EwkejNH3d4

[BioInvent International @BioInvent]

BioInvent Announces Additional Positive Efficacy Data with Single Agent BI-1808 from the Phase 2a anti-TNFR2 program
https://t.co/wY2dDmGyPC

[BioInvent International @BioInvent]

BioInvent and Transgene to Present Promising Initial Phase 1/2a Data on Oncolytic Virus, BT-001, at ESMO 2024 https://t.co/MIuzJuLWUq

[BioInvent International @BioInvent]

BioInvent International Interim Report January-June 2024 released today: https://t.co/FgcWnyTWGV

[BioInvent International @BioInvent]

BioInvent receives Notice of Allowance from USPTO for BI-1910 patent application
Allowed US patent application for anti-TNFR2 antibody BI-1910 covers composition-of-matter protection and the use of antibody to treat cancer.
https://t.co/oYbi6HW1gJ

[BioInvent International @BioInvent]

BioInvent to Present Pipeline Progress at ESMO in September 2024. Two posters to be presented on early clinical projects from BioInvent’s robust pipeline totaling six clinical programs.
- Progress Phase 1 update for BI-1910
- Initial Phase 1 clinical data for BT-001

[BioInvent International @BioInvent]

BioInvent announces new clinical trial collaboration and supply agreement with MSD to evaluate BI-1607 in combination with KEYTRUDA (pembrolizumab) and ipilimumab. Read more: https://t.co/WypZKcYyIm

[BioInvent International @BioInvent]

BioInvent Presents Poster Highlighting Model-Informed Early Clinical Development of anti-TNFR2 agent BI-1808 at PAGE 2024

https://t.co/nTDsgLfqrp

[BioInvent International @BioInvent]

BioInvent gains patent for BI-1808 in China. The patent provides composition-of matter protection for BI-1808 and the use of the antibody for the treatment of cancer.

https://t.co/lHfuE6PF6R

[BioInvent International @BioInvent]

Did you miss our KOL event yesterday? No worries, watch it here, anytime: https://t.co/pBqQbNRpv2

The event features Alexander Eggermont, MD, PhD (University Medical Center Utrecht), on the topic "Where are we going next with immuno-oncology?" and CEO, CMO and CSO.

[BioInvent International @BioInvent]

Today is the Day - don't miss out! Our KOL event starts at 3 pm CEST/9 am EDT. Registration details below.

[BioInvent International @BioInvent]

BioInvent to Host Virtual KOL Event on June 18, 2024, to discuss BioInvent’s lead candidates BI-1808 and BI-1206 and TNFR2 and FcyRIIB are promising targets in immuno-oncology.
To register, visit: https://t.co/qN1Cs0ys04

[BioInvent International @BioInvent]

BioInvent to Host Virtual KOL Event on June 18, 2024, to discuss BioInvent’s lead candidates BI-1808 and BI-1206 and TNFR2 and FcyRIIB are promising targets in immuno-oncology.
To register, visit: https://t.co/qN1Cs0ys04

[BioInvent International @BioInvent]

BioInvent Presents Promising Clinical Efficacy and Safety for anti-TNFR2 agent BI-1808 and Promising Phase 1 Data for BI-1206 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors at ASCO 2024. https://t.co/If5y9v2CYe

[BioInvent International @BioInvent]

BioInvent presents additional promising Phase 1/2a data at EHA 2024 for BI-1206 with rituximab in NHL.
Read the press release: https://t.co/4gMmujApb9